Company Profile

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company's activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed's pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.

Employees

Sector

Biotechnology & Medical Research

More about the company

01-26	Autolus Limited Enters into Master Service Agreement with AGC Biologics S.P.A	CI
25-08-01	Genenta Science S.p.A. Notifies AGC Biologics S.p.A. of its Intent to Terminate Work Statement No. 01	CI
25-07-31	European Commission Approves CAR-T Therapy with Lentiviral Vectors Manufactured by AGC Biologics	CI
24-12-30	Genenta Science S.p.A. and AGC Biologics S.p.A. Enters into the Second Amendment to the Development and Master Services Agreement	CI
24-11-14	Genenta Science S.p.A. Enters into Letter of Intent with AGC Biologics S.p.A	CI
23-02-01	Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement	CI
22-12-12	AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies	CI
22-08-16	RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies	CI
21-06-07	AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility	CI
20-10-12	MolMed Announces Transition of Luca Alberici from the Role of Chief Business Officer	CI
20-08-03	MolMed S.p.A.(BIT:MLM) dropped from S&P Global BMI Index	CI
20-07-23	AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €220 million.	CI
20-07-09	Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration	CI

20-08-06	MolMed S p A : CS_ integrativo del Comunicato dimissioni consiglieri	PU
20-06-08	University of Tartu: Novel DNA analysis will help to identify food origin and counterfeit food in the future	AQ
20-05-08	Karolinska Institutet: Overlooked protein could play important part in pneumonia and COVID-19, researchers say	AQ
20-04-02	University of Bristol: UK genome analysis has important implications for COVID-19 clinical trials	AQ
20-03-12	MolMed S p A : KU awards 38 PhD, 16 M. Phil, two Master of Surgery degrees	AQ

20-09-30	MolMed S p A : Delisting
20-07-13	Atlantia : Borsa Milano parte positiva, Atlantia cede oltre 12% su timori revoca
20-07-10	Atlantia : Borsa Milano in rialzo con Stm, auto e banche, deboli lusso e energia
20-07-10	Atlantia : Borsa Milano in rialzo spinta da buoni dati produzione industriale
20-07-10	Atlantia : Borsa Milano poco mossa in avvio, brillano Atlantia, Molmed

Manager	Title	Age	Since
Alberto Santagostino CEO	Chief Executive Officer	-	2024-10-31
Kasper Møller CTO	Chief Tech/Sci/R&D Officer	-	2019-05-31
Greg Shelton HRO	Human Resources Officer	-	2022-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MOLMED S.P.A.	-.--%	-.--%	-	-	282M
LONZA GROUP AG	-2.54%	-2.84%	-1.90%	+14.52%	50.35B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+439.20%	+499.20%	45.2B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+45.46%	+19.36%	44.71B
BEONE MEDICINES AG	-1.22%	-2.31%	+12.40%	+71.48%	41.24B
CELLTRION, INC.	+0.53%	-1.36%	+16.04%	+48.23%	33.08B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.81B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+22.59%	+116.19%	16.56B
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+15.83%	+27.98%	14.82B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+77.75%	+37.63%	14B
Average	-0.83%	+0.49%	+78.42%	+104.33%	30.86B
Weighted average by Cap.	-1.04%	+0.26%	+94.35%	+121.44%

MolMed S.p.A. Stock

Stocks

MLM

IT0001080248

Biotechnology & Medical Research

Latest news : MolMed S.p.A.

Press Releases : MolMed S.p.A.

News in other languages : MolMed S.p.A.

Managers and Directors : MolMed S.p.A.

Other Biotechnology & Medical Research

Company Profile